Lexicon Pharmaceuticals, Inc.
Veridion Score
Composite trend over time
Why is LXRX moving today?
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for LXRX.
LXRX insider activity
Lexicon Pharmaceuticals, Inc.
No multi-insider buying cluster in the last 90 days
Net buying: $57.4M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-03-03 | 2026-02-28 | McDermott Wendy | Insider | sell | $1.47 | 68,107 | 277,945 | $100K | SEC Form 4 |
| 2026-03-03 | 2026-02-28 | Martens Rachel Yap | Insider | sell | $1.47 | 35,826 | 31,264 | $53K | SEC Form 4 |
| 2026-03-03 | 2026-02-28 | Granowitz Craig B | Insider | sell | $1.47 | 109,098 | 323,430 | $160K | SEC Form 4 |
| 2026-03-03 | 2026-02-28 | Gopinathan Suma | Insider | sell | $1.47 | 24,338 | 150,132 | $36K | SEC Form 4 |
| 2026-03-03 | 2026-02-28 | DeFrancesco Lisa | Insider | sell | $1.47 | 74,572 | 93,869 | $110K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 15 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moLXRX contract awards, year to date.
Public federal awards linked to this ticker.
LXRX lobbying filings, year to date.
Registered lobbying filings matched to Lexicon Pharmaceuticals, Inc..